Floatz logo

Anti Cd30 Car-T Cell

NK/T Cell Lymphoma

Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the NK/T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
Tucidinostat
Ruijin Hospital
Phase 4BB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

Anti Cd30 Car-T Cell is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
C
Indicative ·
39 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
C
Indicative ·
39 / 100
View asset →
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →